- Home
- ICCM vs IGC Comparison
ICCM vs IGC Comparison
Compare ICCM & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | IGC |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.5M | 33.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ICCM | IGC |
|---|---|---|
| Price | $0.66 | $0.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.50 | ★ $4.13 |
| AVG Volume (30 Days) | 375.3K | ★ 496.5K |
| Earning Date | 11-19-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,975,000.00 | $1,106,000.00 |
| Revenue This Year | $13.67 | $3.54 |
| Revenue Next Year | $38.55 | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $0.25 |
| 52 Week High | $1.66 | $0.50 |
Technical Indicators
Market Signals| Indicator | ICCM | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 39.01 | 54.57 |
| Support Level | $0.67 | $0.28 |
| Resistance Level | $0.72 | $0.36 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 5.66 | 86.10 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.